ER+PR+HER2+ breast cancers are responsive to anti-hormonal therapy and inhibitory antibodies against the RTK (e.g., trastuzumab), whereas triple-negative cases suffer from poor outcomes due to a lack of efficient therapies and response biomarkers [9]. This evidence concerns the gene ESR1 and breast carcinoma.